- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01889719
A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR
12. februar 2016 oppdatert av: Rockefeller University
Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006)
This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are safe and whether they will boost immune responses generated by immunizations with a dendritic cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy HIV-uninfected volunteers.
Studieoversikt
Detaljert beskrivelse
This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are safe and whether they will boost immune responses generated by immunizations with a dendritic cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy HIV-uninfected volunteers.
Investigators propose to assess the quality of immunity elicited by immunizations with MVA-CMDR only or by booster immunizations with MVA-CMDR in volunteers previously immunized with a DC-targeted HIV vaccine.
This vaccination regimen can provide the proof-of-concept that DC targeted protein vaccines can prime strong immune responses and therefore be valuable in combination with other vaccine modalities against HIV or other diseases.
Studietype
Intervensjonell
Registrering (Faktiske)
14
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10065
- The Rockefeller University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 62 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Have completed protocol SSC-710 and received either DCVax-001 plus poly ICLC, poly ICLC only or sterile saline. If less than 6 volunteers who originally received placebo (poly ICLC only or sterile saline) under protocol SSC_710 are willing to participate and are found eligible to participate in this proposed study, new volunteers can be enrolled as long as they are eligible according to the remaining inclusion and exclusion criteria below.
- Healthy adult males and females, as assessed by a medical history, physical exam, ECG, and laboratory tests;
- Age of at least 18 years of age on the day of screening and no greater than 62 years at time of vaccination;
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 12 months);
- In the opinion of the principal investigator or designee, has understood the information provided. (Written informed consent needs to be given before any study-related procedures are performed);
- Amenable to HIV risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit;
- Assessed by the clinic staff as being at "low risk" for HIV infection on the basis of sexual behaviors within the 12 months prior to enrollment defined as follows:
- Sexually abstinent OR
- Had two or fewer mutually monogamous relationships with partners believed to be HIV-uninfected and who did not use illicit drugs (illicit drug use or abuse that includes any injection drugs, methamphetamines (crystal meth), heroin, cocaine, including crack cocaine or chronic marijuana abuse) OR
- Had two or fewer partners believed to be HIV-uninfected and who did not use illicit drugs (as defined above) and with whom he/she regularly used condoms for vaginal and anal intercourse;
- If sexually active female, willing to use one effective method of contraception (combined oral contraceptive pill; injectable contraceptive; diaphragm; Intra Uterine Device (IUD); condoms; anatomical sterility in self or partner) at least until 3 months after last immunization. All female volunteers must be willing to undergo urine pregnancy tests at time points as indicated in the Schedule of Procedures.
Exclusion Criteria:
- Confirmed HIV-1 or HIV-2 infection
- Any clinically significant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids immunosuppressive anticancer, or other medications considered significant by the trial physician within the last 6 months
- Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, myopericarditis, grand-mal epilepsy, rheumatologic illness, malignancy, substance abuse) that in the opinion of the investigator would preclude participation
- History of clinically significant eczema or chronic urticaria
- Any laboratory value outside of reference range, with the exception of any non-clinically significant Grade I elevations of liver function tests (AST, ALT, direct/total bilirubin), electrolytes (Na, K, Cl, CO2), CBC, urinalysis as determined by the Principal Investigator or his designee
- Baseline ECG with features that would interfere with interpretation of myo/pericarditis including significant repolarization abnormality, bundle branch block, and AV block
- Within the 12 months prior to enrollment, the volunteer has had excessive daily alcohol use or frequent binge drinking or chronic marijuana abuse or any other use of illicit drugs
- Within the 12 months prior to enrollment, the volunteer has a history of newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), pelvic inflammatory disease (PID), mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies);
- If female, pregnant, planning a pregnancy during the 3-month follow up period after last immunization, or lactating
- Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days prior to study vaccination
- Prior use of medications for HIV PrEP
- Receipt of an investigational product (not vaccine-related) within the last 12 months. Receipt of a non-HIV experimental vaccine(s) within the last 5 years in a prior vaccine trial. Exceptions may be made for vaccines that have subsequently undergone licensure by the FDA. For subjects who have received control/placebo in an experimental vaccine trial, or who have received an experimental vaccine(s) greater than 5 years ago, eligibility for enrollment will be determined by the investigators on a case-by-case basis.
- History of severe local or systemic reaction to vaccination defined as:
- Local: extensive, indurated redness and swelling involving most of the major circumference of the arm, not resolving within 72 hours;
- Systemic: fever > 39.5°C within 48 hours, anaphylaxis, bronchospasm, laryngeal edema, circulatory collapse, convulsions or encephalopathy within 72 hours
- History of immediate type hypersensitivity reaction to eggs or egg products
- Major psychiatric illness
- In the opinion of the investigator, unlikely to comply with protocol
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Vaccination with MVA-CMDR Group 1
Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
|
injections of MVA-CMDR vaccine
|
Aktiv komparator: Vaccination with MVA-CMDR Group 2
Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
|
injections of MVA-CMDR vaccine
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
safety and tolerability of MVA-CMDR vaccine
Tidsramme: 16 weeks
|
safety and tolerability of two intramuscular injections of MVA-CMDR vaccine candidate in healthy HIV-uninfected volunteers
|
16 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Sarah Schlesinger, MD, Rockefeller Univesrity
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2014
Primær fullføring (Faktiske)
1. mai 2015
Studiet fullført (Faktiske)
1. mai 2015
Datoer for studieregistrering
Først innsendt
20. juni 2013
Først innsendt som oppfylte QC-kriteriene
26. juni 2013
Først lagt ut (Anslag)
28. juni 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
17. februar 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. februar 2016
Sist bekreftet
1. februar 2016
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- SSC-0803
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutteringHIV | HIV-testing | HIV-kobling til omsorg | HIV-behandlingForente stater
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationFullførtPartner HIV-testing | Par HIV-rådgivning | Parkommunikasjon | HIV-forekomstKamerun, Den dominikanske republikk, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement og andre samarbeidspartnereUkjentHIV | HIV-uinfiserte barn | Barn utsatt for HIVKamerun
-
University of MinnesotaTilbaketrukketHIV-infeksjoner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS og infeksjonerForente stater
-
CDC FoundationGilead SciencesUkjentHIV-preeksponeringsprofylakse | HIV kjemoprofylakseForente stater
-
Hospital Clinic of BarcelonaFullførtIntegrasehemmere, HIV; HIV PROTEASE HEMMINGSpania
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London og andre samarbeidspartnereRekrutteringHIV | HIV-testing | Kobling til omsorgSør-Afrika
-
Erasmus Medical CenterHar ikke rekruttert ennåHIV-infeksjoner | Hiv | HIV-1-infeksjon | HIV I infeksjonNederland
-
University of WashingtonNational Institute of Mental Health (NIMH)RekrutteringHIV-forebygging | HIV-preeksponeringsprofylakse | GjennomføringKenya
-
University of Maryland, BaltimoreTilbaketrukketHiv | Nyretransplantasjon | HIV-reservoar | CCR5Forente stater
Kliniske studier på MVA-CMDR
-
Henry M. Jackson Foundation for the Advancement...Johns Hopkins University; Karolinska Institutet; University of Miami; Chulalongkorn... og andre samarbeidspartnereRekruttering
-
National Institute of Allergy and Infectious Diseases...HIV Vaccine Trials Network; IPPOX Foundation; CHAVI; MHRPFullført
-
Instituto Nacional de Saúde, MozambiqueEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Swedish...Fullført
-
University of OxfordFullført
-
Fudan UniversityRekruttering
-
Università degli Studi dell'InsubriaFullførtLungekreft | Kirurgi - komplikasjoner | Moral
-
Hospital General Universitario de ValenciaUkjentPostoperative komplikasjoner | Lungekreft | Lungeskade | Lungeneoplasma | Thoracic | Voksen ALLE | Lungebetennelse | Lungeiskemi/hypoksi | Postoperativ respiratorisk komplikasjonSpania
-
University Hospital of FerraraFullført
-
Bavarian NordicFullførtRespiratoriske syncytiale virusinfeksjonerForente stater